View in EDS HTML Full Text PDF Full Text

Cost-Utility Analysis of Faricimab Versus Aflibercept in Treating Neovascular Age-Related Macular Degeneration (nAMD) in the United States.

Saved in:
Bibliographic Details
Title: Cost-Utility Analysis of Faricimab Versus Aflibercept in Treating Neovascular Age-Related Macular Degeneration (nAMD) in the United States.
Authors: Baljoon, Ahmead1 (AUTHOR), Diaby, Vakaramoko2 (AUTHOR), Suther, Sandra1 (AUTHOR), Dutton, Matthew1 (AUTHOR), Ali, Askal1 (AUTHOR), Eljilany, Islam3 (AUTHOR) islam.eljilany@hotmail.com
Source: PharmacoEconomics - Open. May2026, Vol. 10 Issue 3, p457-469. 13p.
Database: Business Source Ultimate
Full text is not displayed to guests.
Description
ISSN:25094254
DOI:10.1007/s41669-026-00643-0